Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of IL-13-PE in Patients With Treatment Refractory Malignancies With a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma

NCT01832974 is registered in ClinicalTrials.gov with INSYS Therapeutics Inc as lead sponsor.

NCT NCT01832974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01832974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of IL-13-PE in Patients With Treatment Refractory Malignancies With a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma
Lead sponsor
INSYS Therapeutics Inc
Phase
Phase 1
Overall status
Terminated
Start date
December 31, 2012
Completion date
September 30, 2014
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adrenocortical carcinoma